Lead Product(s): Allocetra
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Israel Innovation Authority
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding April 13, 2020
The fund is directed towards Enlivex's planned COVID-19 and sepsis clinical programs that will evaluate safety and efficacy of AllocetraTM in both the indications.